We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
+25.49%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$4.28B
AUM Growth
-$319M
(-6.9%)
Cap. Flow
-$726M
Cap. Flow
% of AUM
-16.97%
Top 10 Holdings %
Top 10 Hldgs %
42.06%
Holding
115
New
18
Increased
32
Reduced
19
Closed
30
Top Buys
| 1 |
Universal Health Services
UHS
|
+$97.5M |
| 2 |
Surgery Partners
SGRY
|
+$75.3M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$60M |
| 4 |
Prothena Corp
PRTA
|
+$57.7M |
| 5 |
argenx
ARGX
|
+$49.8M |
Top Sells
| 1 |
Eli Lilly
LLY
|
+$280M |
| 2 |
Biogen
BIIB
|
+$160M |
| 3 |
State Street SPDR S&P Biotech ETF
XBI
|
+$120M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$104M |
| 5 |
Humana
HUM
|
+$103M |
Sector Composition
| 1 | Healthcare | 99.55% |
| 2 | Financials | 0.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.6B
| $337M | 7.88% |
+4,062,000
| New | +$329M |
|
|
2
argenx
ARGX
$54B
| $237M | 5.53% |
625,000
+133,200
| +27% | +$49.8M |
|
3
United Therapeutics
UTHR
$22.6B
| $218M | 5.11% |
785,500
-184,700
| -19% | -$46.6M |
|
4
Neurocrine Biosciences
NBIX
$17.3B
| $213M | 4.97% |
1,780,000
-75,700
| -4% | -$8.87M |
|
|
AKRO
5
DELISTED
Akero Therapeutics
AKRO
| $210M | 4.9% |
3,825,000
+703,000
| +23% | +$30.1M |
|
|
6
Prothena Corp
PRTA
$441M
| $178M | 4.16% |
2,953,000
+986,000
| +50% | +$57.7M |
|
7
Arvinas
ARVN
$534M
| $169M | 3.96% |
4,950,000
+606,500
| +14% | +$25.5M |
|
8
Boston Scientific
BSX
$64B
| $151M | 3.52% |
3,256,700
+718,100
| +28% | +$31.1M |
|
9
Syndax Pharmaceuticals
SNDX
$2.08B
| $149M | 3.49% |
5,861,000
+274,100
| +5% | +$6.39M |
|
10
Ultragenyx Pharmaceutical
RARE
$3.12B
| $139M | 3.24% |
2,990,000
+938,400
| +46% | +$36.9M |
|
11
Sarepta Therapeutics
SRPT
$1.86B
| $137M | 3.19% |
1,055,000
+106,800
| +11% | +$12.4M |
|
12
Madrigal Pharmaceuticals
MDGL
$12.7B
| $125M | 2.92% |
+430,000
| New | +$42.1M |
|
|
13
Universal Health Services
UHS
$8.96B
| $116M | 2.72% |
+825,600
| New | +$97.5M |
|
|
14
Jazz Pharmaceuticals
JAZZ
$15B
| $116M | 2.71% |
727,541
+409,241
| +129% | +$60M |
|
15
Zentalis Pharmaceuticals
ZNTL
$340M
| $104M | 2.42% |
5,150,000
+926,900
| +22% | +$19.9M |
|
16
Acadia Healthcare
ACHC
$2.97B
| $95.9M | 2.24% |
1,165,000
-224,200
| -16% | -$18.5M |
|
|
17
Surgery Partners
SGRY
$2.08B
| $86.7M | 2.03% |
3,112,000
+2,844,400
| +1,063% | +$75.3M |
|
18
DexCom
DXCM
$28.1B
| $85.7M | 2% |
756,800
+289,200
| +62% | +$31.8M |
|
19
AstraZeneca
AZN
$261B
| $81.4M | 1.9% |
600,000
+318,400
| +113% | +$39.9M |
|
|
20
Eli Lilly
LLY
$1.03T
| $79.4M | 1.86% |
217,000
-790,000
| -78% | -$280M |
|
21
Vaxcyte
PCVX
$8.19B
| $77.5M | 1.81% |
1,615,400
+986,700
| +157% | +$38.7M |
|
|
RNAM
22
DELISTED
Avidity Biosciences
RNAM
| $72.7M | 1.7% |
3,275,000
+675,000
| +26% | +$10.1M |
|
23
Natera
NTRA
$39.7B
| $72.3M | 1.69% |
1,798,900
+63,900
| +4% | +$2.63M |
|
24
IDEAYA Biosciences
IDYA
$3.54B
| $69.5M | 1.62% |
3,824,800
+109,400
| +3% | +$1.84M |
|
25
Immunocore
IMCR
$1.76B
| $65.9M | 1.54% |
1,154,000
-925,100
| -44% | -$52.1M |
|
Similar funds
NM
LM
IF
PWAM
CM
LJAC
PO
SH